1. Home
  2. TORO vs SGMT Comparison

TORO vs SGMT Comparison

Compare TORO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Toro Corp.

TORO

Toro Corp.

HOLD

Current Price

$4.86

Market Cap

173.8M

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.13

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TORO
SGMT
Founded
2022
2006
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
173.8M
169.4M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
TORO
SGMT
Price
$4.86
$7.13
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$26.13
AVG Volume (30 Days)
25.3K
1.4M
Earning Date
04-15-2026
05-14-2026
Dividend Yield
36.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.64
$4.50
52 Week High
$8.50
$11.41

Technical Indicators

Market Signals
Indicator
TORO
SGMT
Relative Strength Index (RSI) 45.64 49.49
Support Level $4.89 $7.09
Resistance Level $5.34 $7.39
Average True Range (ATR) 0.23 0.43
MACD 0.01 -0.00
Stochastic Oscillator 43.64 32.77

Price Performance

Historical Comparison
TORO
SGMT

About TORO Toro Corp.

Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: